bioMérieux S.A. (BMXXY)
OTCMKTS · Delayed Price · Currency is USD
13.83
+0.88 (6.80%)
At close: Jul 11, 2025
Instructure Holdings Revenue
In the year 2024, bioMérieux had annual revenue of 3.98B EUR with 8.31% growth. bioMérieux had revenue of 2.08B in the half year ending December 31, 2024, with 7.61% growth.
Revenue
3.98B EUR
Revenue Growth
+8.31%
P/S Ratio
4.10
Revenue / Employee
269.75K EUR
Employees
14,754
Market Cap
16.90B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.98B | 305.20M | 8.31% |
Dec 31, 2023 | 3.67B | 85.60M | 2.39% |
Dec 31, 2022 | 3.59B | 212.90M | 6.31% |
Dec 31, 2021 | 3.38B | 258.00M | 8.27% |
Dec 31, 2020 | 3.12B | 443.40M | 16.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
American Oncology Network | 1.76B |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |